Медико-биологический
информационный портал
для специалистов
 
Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г.  2021 г.  2022 г.  2023 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 14, Art. 82 (pp. 1030-1050)    |    2013       
»

Efficacy of bortezomib, melpahlan and prednisolone (VMP) in patients with newly diagnosed multiple myeloma
Mitina T.A., Golenkov A.K., Trifonova E.V., Lutckaia T.D., Kataeva E.V., Vysotckaia L.L., Dudina G.A., Chernykh Iu.B., Zaharov S.G., Clinushkina E.F., Belousov K.A.

Moscow Regional Research Clinical Institute named after M.F. Vladimirsky



Brief summary

105 patients, not eligible for ASCT, with newly diagnosed multiple myeloma were included in the study. Patients received VMP induction therapy of 8 cycles. Group was randomized to subgroups with the duration of treatment 6 and 9 weeks. Short-term and long-term results were evaluated. Overall response rate was 75,2% (78 patients). 46 patients (43,8%) achieved partial response. 33 patients (31,4%) achieved higher response (VGPR + CR), with CR in 12 patients (11,4%) . Evaluating long-term results, it should be noticed that median PFS was 40 and 32 months (p > 0,05). It is important that median OS by all response categories are still not achieved (median follow-up 32,3 months). All known variants of VMP program are characterized by low hematologic and neurologic toxicity and improved quality of life.


Key words

multiple myeloma, Velcade





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Golenkov A.K., Barishnikov A.U., Karaylov A.V., Mitina T.A. Mnojestvennaya mieloma // Moskva. – 2009.


2. Bessmelcev C.C., Stelmashenko L.B., Karyagina E.B. i dr. Lechenie pojilih pacientov s mnojestvennoi mielomoi na sovremennom etape // Onkogematologiya. – 2010.-№4.-C. 6-13.


3. Palumbo A., Bringehen S., Caravita T. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in eldery patients with multiple myeloma: randomized controlled trial // Lancet. -2006. – Vol.367 (9513). – P.825- 831.


4. Mateos M., V, Richardson P.G., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in phase III vista trial // J. Clin. Oncol.- 2010.-№ 28 (13). - P. 2259-2266.


5. Palumbo A., Bringehen S., Rossi D. et al. Bortezomib — melphalan -prednisone - thalidomide followed by maintenance with bortezomib- thalidomide versus bortezomib - melphalan -prednisone for initial treatment of multiple myeloma: randomized controlled trial //J. Clin. Oncol. – 2010. - №28 (34). –P.5101—5109.


6. Jakuboviak A.J. , Griffith K., Reece D.E. et al. Lenalidomide, bortezomib, pegilated liposomal doxorubicin and dexametasone in newly diagnosed multiple myeloma: a phase ½ Multiple Myeloma Reseach Consorcium trial //Blood.- 2011. –Vol.118, №3. – P.535-543.


7. Durie B.G.M., Harousseau J.L., S.Miguel J. et al. International uniform response criteria for multiple myeloma. International uniform response criteria for multiple myeloma //Leukemia. – 2006. – Vol.20, №9. – P. 1467 -1473.


8. Morabito F., Gentile M., Mazzone S. et al. Safety and efficacy of bortezomib — melphalan -prednisone- thalidomide followed by bortezomib—thalidomide maintenance (VMPT-VT) versus bortezomib — melphalan - prednisone (VMP) in untreated multiple myeloma patients with renal impairment //Blood. – 2011. – Vol.118, №22. – P.5759 - 5766.


9. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, v 3.0. http:// ctep.cancer.gov/protocol Development/electronic


a publication/ctc.htm#ctc_v3.0 Accessed October 10.2010.


10. De Groot V, Beekerman H., Lankhorst G. How to measure comorbidity: a critical review of available methods // J. Clin. Epidimiol.- 2003. –Vol.56, №3.- P.221 - 229.


11 . Kaplan E.L. ., Meier P. Nonparametric estimation from incomplete observation // J. Am. Statist. Ass. -1958. -53(282). – P.457-481.


12. Durie B.G. , Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured cell mass with presunting clinical features, response to treatment, and survival // Cancer. -1975.- Vol.36, №3.- P.842-854.


13. Greipp P.R., San Miguel J.F., Durie B.G. et al. International Staging System for multiple myeloma // J. Clin. Oncol. – 2005. – Vol.23, №15. – P.3412-3420.


14. Schag S.S., Heinrich R.L., Gaiz P.A. Karnofsky performance status revisited: Reability, validity, and guadelines // J. Clin. Oncology. -1984. – Vol.2, №3. – P.187-193.


15. Raikumar S. V., Harousseau J.L., Durie B.G.M. et al. Concensus recommendation for the uniform reporting of clinical trials: report of the International Myeloma Workshop Concensus Panel 1 // Blood. – 2011. – Vol.117, №18.- P. 4691 - 4695.


16. San Miguel J.F., SchlagR., Khuageva N.K. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma //N. Engl. J. Med.- 2008. –Vol.359. – P.906-917.


17. Mateos M.V., OriolA., Martinez-Lopes J. et al. Bortezomib, melphalan and prednisone versus bortezomib, thalidomide and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in eldery patients with untreated multiple myeloma: a randomised trial //Lancet Oncol.- 2010. – Vol.11, №10. – P.934—941.


18. Kumar S., Flinn J., Richardson P.G. et al. Randomised, multicenter phase 2 study (EVOLUTION) of combination of bortezomib, dexametasone, cyclophosphamide and lenalidomade in previously untreated multiple myeloma //Blood. – 2012. – Vol.119, №19. – P.4373 - 4382.


19. San Miguel J., Dimopoulos M.A., Schlag R. et al. Superior Survival with VMP versus MP after longer follow up and response to subsequent therapy in VISTA // Clin. Lymphoma and Myeloma.- 2009. - XII International Myeloma Workshop 26th Feb.— 01 March, Washington, DC, USA.- Abst.book- abst. 232 - P. 33.


20. Dimopoulos M.A., Richardson P.G., Schlag R. et al. VMP in renaly impaired new diagnosed MM patients: cohort analysis of the VISTA study // Clin. Lymphoma and Myeloma. – 2009. - XII International Myeloma Workshop 26th Feb.-Ol March, Washington, DC, USA.- Abst. book - adst. 166 – P. 24.


21. Palumbo A., Cavallo F. Have drug combinations supplanted stem cell transplantation in myeloma // Blood. – 2012. – Vol.120, №24. - P.4692—4698.


22. Gay F., Larocca A., Wierman P. et al. Complete response correlates with long-term progression-free and overall survival in eldery myeloma treated with novel agents: analysis of 1175 patients // Blood. – 2011.- Vol.117, №11. - P.3025 - 3031.


23. Harrison S.J., Hang Quach, Link E. et al. A high rate of durable response with romidepsin, bortezomib and dexamethasone in relapse or refractory multiple myeloma // Blood. – 2011. –Vol. 118, №24 – P. 6274-6283


24. Heeg B., Agthoven M., Liwing J. et al. Optimal treatment sequencing in multiple myeloma an exploratory modeling approach // American Society of Hematology Annual meeting.- 4-7 December.- 2010.- Orlando, FI. USA - abst. Blood. -2010. – Vol.116, №21. - abstr. 3046 - P.1255.


25. Bringen S., Larocca A., Rossi D. et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients // Blood. – 2010. – Vol.116, №23. – P.4745-4753.


26. Mateos M. V, Martin M.L., Gonzales Y. et al. Bortezomib (velcade), Melphalan/Prednisone (VMP) versus velcade/thalidomide/ prednisone (VTP) in eldery //Clin. Lymphoma and Myeloma. – 2009.- XII International Myeloma Workshop 26th Feb.—01 March.- Washington, DC, USA - abst.book. - abst. 154- P. 20- 21.


27. Rajkumar S. V. Initial treatment of multiple myeloma //Hematol. Oncol.- 2013.- Vol.3l, Suppl1. – P. 33-37



Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100